Sanofi

Sanofi, a 10% owner of Sanofi, reported multiple transactions in common stock on August 10, 2026.

Sanofi, a 10% owner of Sanofi, purchased 300,000 shares of common stock on August 6, 2026 for $17.00 per share.

Sanofi reported 10 holdings worth $534.0M for the period ended June 30, 2026.

Sanofi's latest SEC filing reveals significant investments in several biotechnology companies, including Inhibrx Biosciences and MeiraGTx Holdings.

Sanofi's latest 13F filing reveals its equity positions in eight biotechnology and pharmaceutical companies as of December 31, 2025, totaling over $310 million.

Sanofi's latest 13F filing reveals its public equity holdings as of September 30, 2025, totaling over $260 million across nine biotechnology and pharmaceutical companies.

Sanofi's latest 13F filing reveals its equity portfolio as of June 30, 2025, totaling over $175 million across ten distinct holdings.

Sanofi's latest 13F filing unveils substantial holdings in several biotech companies, reflecting its investment strategy in the sector.

Amundi and Amundi Asset Management have updated their Schedule 13G filing regarding their beneficial ownership of Sanofi common stock.

Sanofi has reported beneficial ownership of 5.71% of AgomAb Therapeutics' common shares, totaling 2,783,096 shares.

Amundi and Amundi Asset Management have filed a Schedule 13G, reporting beneficial ownership of 5.04% of Sanofi's common stock and American Depositary Receipts.

Amundi and Amundi Asset Management have filed an amendment to their Schedule 13G, reporting beneficial ownership of 5.21% of Sanofi's common stock and American Depositary Receipts.

Amundi and Amundi Asset Management report a 5.03% beneficial ownership stake in Sanofi, primarily for investment purposes.

Amundi and its subsidiary, Amundi Asset Management US, Inc., have filed an amended Schedule 13G, disclosing a combined beneficial ownership of 4.8% in Sanofi's common stock and American Depositary Receipts as of March 31, 2025.